Dr. Jones is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Main Street Suite 520
Cambridge, MA 02142
Education & Training
Ohio State University Fisher College of BusinessMBA, 2015 - 2017- University of Texas School of Public HealthMPH, 2004 - 2006
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Michigan Medical SchoolClass of 2000
Certifications & Licensure
NY State Medical License 2018 - 2025
NJ State Medical License 2017 - 2023
OH State Medical License 2006 - 2018
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 1714 citationsTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger
The New England Journal of Medicine. 2013-07-03 - 46 citationsRelation of Murine Thoracic Aortic Structural and Cellular Changes With Aging to Passive and Active Mechanical PropertiesJason B. Wheeler, Rupak Mukherjee, Robert E. Stroud, Jeffrey A. Jones, John S. Ikonomidis
Journal of the American Heart Association. 2015-02-25 - 76 citationsTight Binding Inhibition of Protein Phosphatase-1 by Phosphatidic Acid SPECIFICITY OF INHIBITION BY THE PHOSPHOLIPIDJeffrey A. Jones, Yusuf A. Hannun
The Journal of Biological Chemistry. 2002-05-03
Journal Articles
- Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical TrialsSteven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaJeffrey A Jones, William Wierda, Clinical Cancer Research
Press Mentions
- Shop TalkNovember 25th, 2017
Idelalisib Use Expands with New CLL Indication PendingJuly 30th, 2015
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsAugust 6th, 2023
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
